
Sundial Growers SNDL
$ 1.58
-2.17%
Annual report 2024
added 01-17-2026
Sundial Growers Operating Income 2011-2026 | SNDL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Sundial Growers
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -132 M | -185 M | -52.4 M | -27.6 M | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.6 M | -185 M | -99.4 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
-117 M | $ 1.14 | -4.62 % | $ 123 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
-726 M | $ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
-34.4 M | $ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
431 K | $ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.25 | - | $ 21.8 M | ||
|
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.62 | 0.62 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
963 M | $ 6.75 | -3.3 % | $ 2.46 B | ||
|
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | ||
|
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | ||
|
Organogenesis Holdings
ORGO
|
-1.28 M | $ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
-73.4 M | $ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
113 M | $ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
-283 M | $ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
-6.67 M | $ 1.22 | 27.44 % | $ 28.5 M | ||
|
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.33 | 1.06 % | $ 4.13 M | ||
|
Relmada Therapeutics
RLMD
|
-104 M | $ 3.93 | 5.01 % | $ 118 M | ||
|
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
-244 M | $ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
-1.37 B | $ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-130 M | $ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
72.7 M | $ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
-36.9 M | $ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
1.61 B | $ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
-31.6 M | - | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
-3.32 M | $ 0.83 | -9.94 % | $ 3.58 M |